ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer Longming LiangHansi ChenFanghong Li Preclinical Studies 08 June 2022 Pages: 875 - 883
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer Danping YuanYong TaoZhaonan Yu Preclinical Studies Open access 21 June 2022 Pages: 884 - 894
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells Sai-Fung ChungSuet-Ying TamYun-Chung Leung Research Open access 20 July 2022 Pages: 895 - 904
Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines Risa Mia SwainLisett ContrerasRenato J Aguilera Research 06 July 2022 Pages: 905 - 921
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer Qun YeZiwei JiangLixia Pei Research Open access 27 June 2022 Pages: 922 - 933
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel Minoru HoriuchiTakehiro UemuraAkio Niimi Research 27 June 2022 Pages: 934 - 943
Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma Janki M. DesaiAniruddha S. KarvePankaj B. Desai Research 08 July 2022 Pages: 944 - 952
3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors Sofia I. BärBernhard BiersackRainer Schobert Research Open access 07 July 2022 Pages: 953 - 961
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes Tinnabhop SantadkhaWanwisa SkolpapHasan UludaÄŸ Research 14 July 2022 Pages: 962 - 976
Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport Zelin DuanZhiyun ZhouHongjian Zhang Research 14 July 2022 Pages: 977 - 989
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors Todd BauerByong Chul ChoShubham Pant Research Open access 29 June 2022 Pages: 990 - 1000
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors Filip JankuSeung-Hoon BeomSun Young Rha Research Open access 08 July 2022 Pages: 1001 - 1010
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors Yoshito KomatsuTsuneo ShimokawaKazuo Kasahara Research Open access 06 August 2022 Pages: 1011 - 1020
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors Toshio ShimizuTakako Eguchi NakajimaDavid Liu Research 06 August 2022 Pages: 1021 - 1031
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies Yu SunakawaKeishiro TakahashiNobuyuki Yamamoto Research Open access 30 June 2022 Pages: 1032 - 1041
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors Xiaofei ZhouUlka VaishampayanNeeraj Gupta Research Open access 06 August 2022 Pages: 1042 - 1050
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study Stergios J. MoschosShahneen SandhuKeith T. Flaherty PHASE I STUDIES Open access 30 May 2022 Pages: 1051 - 1065
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer Hisao ImaiYoshiaki NagaiHiroshi Kagamu Research Open access 24 June 2022 Pages: 1066 - 1079
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial M MegoD SvetlovskaM Chovanec Research 28 June 2022 Pages: 1080 - 1086
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors Nabil AdraDavid J. VaughnDarren R. Feldman Research 27 June 2022 Pages: 1087 - 1094
Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study Tiandong KongLu ChenDanna Liu Research 05 July 2022 Pages: 1095 - 1105
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study Sae OhwadaAkiko TodakaKentaro Yamazaki SHORT REPORT 28 July 2022 Pages: 1106 - 1116
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study Yu XuRong GuoJie Jin Research Open access 14 July 2022 Pages: 1117 - 1124
Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma Peng YuanJinhua SongBaoan Chen Short Report 06 July 2022 Pages: 1125 - 1132
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 Matteo RepettoEdoardo CriminiGiuseppe Curigliano Short Report 25 May 2022 Pages: 1133 - 1136
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report Kei KunimasaNaotoshi SugimotoKazumi Nishino Case Report 03 June 2022 Pages: 1137 - 1140
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma Juanyan LiaoHui GuanShuang Zhang Case Report Open access 21 June 2022 Pages: 1141 - 1145
The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model Haomin LinBin LuoSong Su Review 20 June 2022 Pages: 1146 - 1152
Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome Yang HeWeijin FangChunjiang Wang Research 22 July 2022 Pages: 1153 - 1159
Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion Xinyi LinXiaojuan YangMei He Letters to the Editor 24 May 2022 Pages: 1160 - 1163
Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients Chao LiMengdong ZhangXiaodong Zhang Author Correction Open access 05 July 2022 Pages: 1164 - 1164